| TOTAL: $332.92M | ||||
| Company (Symbol)# |
Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| Advaxis Inc. (OTC BB:ADXS) | Placement of unsecured convertible promissory notes | W for 3.313S | $1.325 | Advaxis completed a $1.325M financing (10/28) |
| Adventrx Pharmaceuticals Inc. (AMEX:ANX) | Registered direct offering | N/A | $11.3 | Adventrx raised $11.3M by placing shares of its Series D convertible preferred stock (10/6) |
| Aeolus Pharmaceuticals Inc. (OTC BB:AOLS) | Private placement | 5.9U | $1.65 | Aeolus completed a $1.65M financing with several existing institutional investors, all of which are affiliates of Xmark Opportunity Partners LLC; Aeolus sold 5.9M units, each comprising one share of common stock and a seven-year warrant to purchase up to two additional shares, priced at 28 cents each (10/7) |
| Aeterna Zentaris Inc. (Canada; AEZS) | Registered direct offering | 4.58S and W for 1.83S | $5.5 | Aeterna raised $5.5M in the offering (10/20) |
| Alfacell Corp. (PK:ACEL) | Private placement | N/A | $3.25 | Alfacell closed a private placement with Charles Muniz, the company's president, CEO and chief financial officer, and certain trusts and individuals related to current investor James O. McCash, Europa International Inc. and Unilab LP (10/20) |
| Amarin Corp. plc (Ireland; AMRN) | Investment | N/A | $70 | Amarin raised $70M in the financing led by Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital; the new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavis-tock Life Sciences Company and RA Capital (10/13) |
| A.P. Pharma (APPA) | Private placement | N/A | $13.1 | A.P. Pharma raised $13.1M in a private placement in two tranches (10/20) |
| ARYx Therapeutics Inc. (ARYX) | Equity financing facility | N/A | | ARYx secured a facility to sell up to $35M shares of common stock to Commerce Court Small Cap Value Fund Ltd. over a 24- month period (10/7) |
| Bionovo Inc. (BNVI) | Private placement | 3.2U | $20 | Bionovo raised $20M through the sale of up to 3.2M units, each consisting of 10 shares and 10 warrants, priced at $6.20 each (10/2) |
| Biotie Therapies Corp. (Finland; PK:BORPF) | Equity deal | N/A | €20 ($30) |
Biotie secured $30M through YA Global Masters SPV Ltd. |
| Cardium Therapeutics Inc. (AMEX:CXM) | Direct offering | N/A | $6 | Cardium raised $6M in a direct offering (10/15) |
| Catalyst Pharmaceutical Partners Inc. (CPRX) | Registered direct offering | 3.97S | $3.97 | Catalyst closed its offering of 3.97M shares at $1 each for gross proceeds of $3.97M (10/7) |
| Cel-Sci Corp. (AMEX:CVM) | Exercise of warrants | N/A | $10 | Cel-Sci received more than $10M over the past 60 days through the exercise of warrants by investors to purchase the company's common stock (10/26) |
| Columbia Laboratories Inc. (CBRX) | Registered direct offering | 10.9S and W for 5.45S | $11.8 | Columbia raised $11.8M through the offering; Oppenheimer & Co. Inc. acted as lead placement agent and The Benchmark Co. LLC acted as co-placement agent (10/23) |
| Corcept Therapeutics Inc. (CORT) | Private placement of stock and warrants | N/A | $18 | Corcept raised $18M through the financing; Thomas Weisel Partners LLC acted as exclusive placement agent (10/13) |
| Corgenix Medical Corp. (OTC BB:CONX) | Credit facility | N/A | $1.75 | Corgenix secured a $1.75M credit facility providing initial funding of $1.1M in an asset-based financing from Summit Financial Resources LP (10/6) |
| DARA BioSciences Inc. (DARA) | Private placement of units | 1.4U | $0.75 | DARA raised $750,000 through the sale of 1.4M units, each unit comprising one share and 0.50 warrants to purchase one share, priced at $0.5357 per unit; Moody Capital Solutions Inc. acted as placement agent (10/13) |
| Galapagos NV (Belgium; BR:GLPG) | Private placement | 2.1S | €18.2 ($27.1) | Galapagos raised $27.1M through the sale of shares to select institutional investors (10/16) |
| Hana Biosciences Inc. (OTC BB:HNAB) | Private placement of units | N/A | $12.4 | Hana completed a private placement of units, raising $12.4M (10/9) |
| Inhibitex Inc. (INHX) | Private placement of stock and warrants | 18S and W for 8.1S | $23 | Inhibitex raised $23M through OVT funds, OrbiMed Advisors, New Enterprise Associates and Great Point Partners, and other existing investors |
| Lexicon Pharmaceuticals Inc. (LXRX) | Private placement | 15.46S | $23.19 | Lexicon raised $23.19M through the placement of 15.46M shares with Invus LP; it concurrently conducted a public offering of 22.8M shares, raising $34.2M (10/8) |
| Med BioGene Inc. (Canada; CDNX:MBI) | Private placement | 4.5U | C$0.36 ($0.34) | Med BioGene closed the third and final tranche of a placement to SEP Capital Corp. (10/8) |
| MethylGene Inc. (Canada; TSX:MYG) | Investment | 3.6S | $1.5 | MetheylGene issued 3.6M shares to Otsuka Pharmaceutical Co. Ltd. at 43 cents each, raising $1.5M (10/15) |
|
NanoViricides Inc. (OTC BB: NNVC) |
Private placement |
N/A | $4.3 | NanoViricides raised more than $4.3M through the issuance of restricted shares and warrant con- versions in private placements (10/5) |
| Oncolytics Biotech Inc. (Canada; ONCY) | Exercise of warrants | 3.235W | $5.8 | Oncolytics raised proceeds of about $5.8M resulting from the exercise of all 3.235M warrants (10/26) |
| Pro-Pharmaceuticals Inc. (AMEX:PRW) | Private placement | N/A | $0.325 | Pro-Pharmaceuticals closed a $325,000 tranche of a private placement of up to $6M with 10X Fund LP; the tranche brings the total raised to date to $3.8M (10/6) |
| ReGen Biologics Inc. (OTC BB:RGBI) | Bridge financing | N/A | $1.75 | ReGen entered a bridge financing for up to $3M in secured convertible notes and closed on the first tranche receiving $250,000 in immediately available funds and commitments for $1.5M to be provided in increments (10/6) |
| Repros Therapeutics Inc. (RPRX) | Private placement of common stock | 3.5S | $4.4 | Repros raised $4.4M in an agreement with institutional investors (10/8) |
| Rexahn Pharmaceuticals Inc. (AMEX:RNN) | Registered direct offering | 6.07S | $5 | Rexahn raised $5M offering the shares at $0.8234 each; investors also will receive warrants to purchase 2.125 shares at $1 each; Rodman & Renshaw acted as exclusive placement agent (10/19) |
| Sernova Corp. (Canada; TSX: SVA) | Private placement | 6.6U | C$1 ($0.94) | Sernova is raising $940,618 through a placement of up to 6.6M units, each unit comprising one common share and one share purchase warrant priced at C15 cents (10/7) |
| StemCells Inc. (STEM) | Private placement | 10S | $12.5 | StemCells raised about $12.5M through the sale of 10M shares to institutional investors at a price of $1.25 per share; the investors also will receive warrants to buy about 4M shares at $1.50 per share; Chardan Capital Markets LLC served as the placement agent (10/28) |
| Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) | Private placement of units | 8.3U | C$1.14 ($1.1) | Stem Cell entered an agreement with J.F. Mackie & Co. Ltd. to raise $1.1M through the sale of 9.5M units priced at C12 cents apiece (10/8) |
| ThromboGenics NV (Belgium; BR:THR) | Exercise of warrants | N/A | €0.6 ($0.882) | ThromboGenics raised $882,491 as a result of the exercise of warrants by a number of the firm's employees (10/9) |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. # Unless otherwise indicated, shares are traded on the Nasdaq exchange; @ Refers to the date of the press release. ** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.N/A = Not applicable; ND = Not disclosed. AMEX = American Stock Exchange; BR = Brussels Stock Exchange; CDNX = Canadian Venture Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange. | ||||